Last 47.75 GBp
Change Today -2.00 / -4.02%
Volume 290.1K
IMM On Other Exchanges
Symbol
Exchange
London
Berlin
As of 11:35 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

immupharma plc (IMM) Snapshot

Open
49.75 GBp
Previous Close
49.75 GBp
Day High
50.75 GBp
Day Low
46.50 GBp
52 Week High
10/30/14 - 66.00 GBp
52 Week Low
06/6/14 - 41.50 GBp
Market Cap
42.3M
Average Volume 10 Days
97.6K
EPS TTM
-0.05 GBp
Shares Outstanding
88.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUPHARMA PLC (IMM)

Related News

No related news articles were found.

immupharma plc (IMM) Related Businessweek News

No Related Businessweek News Found

immupharma plc (IMM) Details

ImmuPharma plc, a drug discovery and development company, is engaged in the development of drugs based on peptide therapeutics to treat serious medical conditions. The company’s lead product candidates include the Lupuzor, which has completed Phase IIb clinical trial for the treatment of lupus autoimmune and inflammatory disease; IPP-204106, a nucleolin/nucleophosmin antagonist has completed Pre-clinical and Phase I/IIa clinical trials for the treatment of cancer; IPP-201007 that is in pre-clinical development trials for the treatment of inflammatory/allergic conditions, such as asthma and rheumatoid arthritis; IPP-102199, which is in pre-clinical development trials is used for the treatment of moderate and severe pain; and IPP-203101, a peptide-based antibiotic is in pre-clinical development trials for the treatment of methicillin-resistant staphylococcus aureus and other hospital-acquired infections. Its discovery pipeline includes heterocyclic ureas scaffolds; and peptide to drug converting technology. The company has collaboration arrangements with the Centre National de la Recherche Scientifique. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

7 Employees
Last Reported Date: 05/23/14
Founded in 1999

immupharma plc (IMM) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 80.1K GBP
President, Chief Scientific Officer and Direc...
Total Annual Compensation: 383.4K GBP
Compensation as of Fiscal Year 2013.

immupharma plc (IMM) Key Developments

Immupharma Plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended 30 June 2014

ImmuPharma Plc announced unaudited consolidated earnings results for the six months ended 30 June 2014. For the period, the company reported operating loss of £1,818,412, loss before taxation of £1,832,513, loss for the year of £1,833,475, loss attributable to equity holders of the parent company of £1,833,475 or 2.23 pence per basic and diluted share, cash used in operations of £1,882,875 compared to the operating loss of £1,852,929, loss before taxation of £1,834,085, loss for the period of £1,769,951, loss attributable to equity holders of the parent company of £1,769,951 or 2.17 pence diluted per share, cash used in operations of £1,510,284 for the previous year.

ImmuPharma PLC Gears Up to Start Pivotal Phase III Trial

ImmuPharma PLC announced that Phase III activities of its lead compound Lupuzor™ will soon commence. Following advanced discussions and after completing detailed due diligence with a potential partner, ImmuPharma has started the preparatory steps for Lupuzor's ™ pivotal phase III clinical trials. Before these initial activities are completed, it is expected that a further agreement to develop Lupuzo™ will be finalised and signed which will see Immupharma and the potential partner fund the phase III trials. This agreement will also allow the partner to run the phase III pivotal programme based on the strengthened study protocol agreed between ImmuPharma and the FDA.

ImmuPharma Plc Announces Update of New Nucant Patents

ImmuPharma Plc announced that the US Patent and Trademark Office has granted a notice of allowance for an "optically pure" version of ImmuPharma's Nucant family. A similar grant has been obtained from the EU, Japanese and Australian patent offices. The patent was developed by ImmuPharma in collaboration with the CNRS (Centre National de la Recherche Scientifique). This composition of matter patent importantly provides: Longer exclusivity; Additional and reinforced protection of ImmuPharma's Nucant programme; A multitude of further indications in addition to cancer. This new patent family covers millions of peptide constructs (i.e. preventing other companies from working in the area) and also expands the potential uses to include angiogenesis related conditions such as age-related macular degeneration, diabetic retinopathy and wound healing as well as cancer selective targeting systems (Nucants target selectively the cancer cells through binding to nucleolin, a protein over expressed in cells that proliferate quickly). The patent exclusive rights belong to ELRO Pharma, one of ImmuPharma's wholly owned subsidiaries. ELRO Pharma is focusing on pioneering research related to this Nucant family of molecules.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMM:LN 47.75 GBp -2.00

IMM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMM.
View Industry Companies
 

Industry Analysis

IMM

Industry Average

Valuation IMM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 10.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUPHARMA PLC, please visit www.immupharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.